Authors


Jai Seth

Latest:

Getting to Clinical Trial Diversity

Differing levels of trust in clinical trials information channels across diverse populations is examined in this research.


Leslie Pascaud

Latest:

Creating Future-Ready Teams for Digital Clinical Trials

The need for specific capabilities to suit DCT business models is creating new challenges in team building, training, and development.


David Alsadius, MD, PhD

Latest:

Where Innovation and Patients Meet to Improve Cancer Care

Promising scientific advances are pacing oncology drug development.


Ann Neuer

Latest:

Revamping Site Feasibility as Trials Become Decentralized

How asking better questions and leveraging site databases can expand access to more patients.


Science 37

Latest:

How to Operationalize Infectious Disease Trials with a Virtual Site

In this playbook, learn how a virtual site solution expands access to infectious disease clinical trials by allowing patients to enroll and participate from anywhere.


Yong Li Fern

Latest:

The ICR-CRM-IQVIA Research Network Collaboration Experience

A discussion of the impact of a strategic alliance in to facilitate operational success at the clinical trial site level in Malaysia.


Mikael Forsby

Latest:

eSource Interoperability Between EHR and EDC

Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.


Joy Y. Wu

Latest:

Pandemic Challenges and Opportunities for Gender Equity in Clinical Research

Industry must act now to minimize effects of COVID-19 on clinical research.


Mats Sundgren, PhD

Latest:

Harnessing Unstructured Data and Hospital Interoperability

The potential of next-generation platforms in transforming patient recruitment.


Derk Arts

Latest:

Debunking Top 5 Myths about Digital Twins in Clinical Trials

Addressing misconceptions as industry becomes more familiar with AI and ML.


Noelle Clifford

Latest:

Microbiology is Vital to Compliance to Annex 1 and Risk-Based Regulation

The revision of Annex 1 clearly calls out the use of quality risk management to identify potential risks to quality and the implementation of a contamination control strategy.


Pete Tarasov

Latest:

6 Steps During Pandemic to Support the Needs of Patients and Sites

The latest FDA and EMA guidelines permit sites, sponsors, and CROs to adjust their operations to meet changing conditions for ongoing trials, including some concerning the safety of participants, that must be met in order for new solutions to be considered.



Natalia Muhlemann

Latest:

Employing the Power of Bayesian Methods to Expedite Learning

Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.



Nadir Ammour, MBA, DMD

Latest:

Innovations in Data Capture Transforming Trial Delivery

Advances in technology open door for improved EHR to EDC transfer process.


Aswin Chandrakantan

Latest:

Navigating Clinical Trial Recruitment in the Midst of COVID-19

Many companies during this time of social distancing have paused trial recruitment completely to focus on currently recruited patients, while others rethink their strategy to better accommodate the new digital-only reality.


Dan Ayala

Latest:

What’s Complicating Good Data Practices and Data Integrity?

Companies must be able to defend the fidelity and confidentiality of all records and data generated throughout a product’s entire lifecycle, starting with the earliest points in research.


Amandine Manon, PharmD

Latest:

FDA’s Project Optimus Guidance: Highlights and Tips for Success for Oncology Drug Developers

January 2023 guidance from FDA on dosages in oncology provides further context on expectations with Project Optimus.


Elisabeth Coart, PhD

Latest:

Integration of Biomarker Validation in Oncology Trials

Recent case study highlights the importance of applying statistical rigor throughout the development and validation processes of biomarkers.


Chris Ingram, Bsc (Hons)

Latest:

Evolution of the UK Legislative Framework for Clinical Trials

New proposals aim to create higher standards for trial regulation.


Michael G. Kelly, PhD

Latest:

Rare Disease Clinical Trials: Strategies Learned from Duchenne Muscular Dystrophy

Approaches sponsors, CROs, and investigators can take from the DMD experience.



Max Luccock

Latest:

Survey Results: GCP Quality and Risks in Decentralized Clinical Trials

Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.


Mac Winslow

Latest:

Considerations to Reach Underrepresented Groups

Regulatory compliance, collaboration, and effective use of technology among ways CROs can overcome challenges.


Brandy Morneau

Latest:

How to Navigate the Clinical Trial Complexities in a Post-COVID World

With various COVID-19 vaccine trials underway, a seamless clinical research process has never been more critical.


Matthew Satterthwaite

Latest:

How Sponsors Can Use Health Decision Science to Improve Clinical Trial Recruitment and Retention

Examining the behaviors of clinical trial stakeholders to better understand challenges in patient participation.


Robyn Owens

Latest:

Aligning Patient Burden with Planetary Burden

How making trial participation easier can reduce the impact on the environment.



David Li, MD, PhD

Latest:

Initial Design Considerations for Immuno-Oncology Trials

Perspectives and insights regarding regulatory considerations when planning and conducting immunotherapy studies.

© 2024 MJH Life Sciences

All rights reserved.